Synjardy XR 12.5 mg/1

Synjardy XR 12.5 mg/1 is an extended-release tablet combining empagliflozin and metformin hydrochloride. It is designed to support blood sugar management in adults with type 2 diabetes. This medication is intended for oral use and is manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.

Synjardy XR 12.5 mg/1 is commonly used to help manage blood sugar levels in adults with type 2 diabetes. The combination of empagliflozin and metformin hydrochloride works to improve glycemic control. This medication is often prescribed as part of a broader treatment plan that includes diet and exercise.

Common effects of Synjardy XR 12.5 mg/1 may include symptoms such as nausea, diarrhea, and headache. Some individuals may experience urinary tract infections or hypoglycemia. It is important to monitor for any unusual symptoms and consult a healthcare provider if they persist or worsen.

Synjardy XR 12.5 mg/1 should be handled with care, especially for individuals with kidney problems or a history of pancreatitis. It is important to follow the prescribed dosage and administration instructions. Always inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Synjardy XR 12.5 mg/1 may interact with certain medications, including diuretics, insulin, and other drugs that affect blood sugar levels. Alcohol consumption should be avoided as it can increase the risk of lactic acidosis. Always consult a healthcare provider before starting any new medication.